Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

BCLI

Brainstorm Cell Therapeutics, Inc.

Oct 04 • 04:00PM ET

2.33

Dollar change -0.04
Percentage change -1.69	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.40	Insider Own	9.14%	Shs Outstand	5.32M	Perf Week	-30.19%
Market Cap	12.40M	Forward P/E	-	EPS next Y	-3.30	Insider Trans	-7.45%	Shs Float	4.83M	Perf Month	-43.92%
Income	-12.75M	PEG	-	EPS next Q	-0.53	Inst Own	15.34%	Short Float	1.93%	Perf Quarter	-56.54%
Sales	0.00M	P/S	-	EPS this Y	57.50%	Inst Trans	-	Short Ratio	2.95	Perf Half Y	-76.14%
Book/sh	-0.66	P/B	-	EPS next Y	-29.41%	ROA	-223.03%	Short Interest	0.09M	Perf Year	-18.25%
Cash/sh	0.65	P/C	3.57	EPS next 5Y	-	ROE	-	52W Range	2.01 - 11.89	Perf YTD	-43.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.56%	ROI	-	52W High	-80.40%	Beta	0.37
Dividend TTM	-	Quick Ratio	0.50	Sales past 5Y	0.00%	Gross Margin	-	52W Low	15.92%	ATR (14)	0.42
Dividend Ex-Date	-	Current Ratio	0.50	EPS Y/Y TTM	62.04%	Oper. Margin	0.00%	RSI (14)	24.16	Volatility	19.53% 11.16%
Employees	29	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	30.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	73.42%	Payout	-	Rel Volume	2.62	Prev Close	2.37
Sales Surprise	-	EPS Surprise	214.29%	Sales Q/Q	-	Earnings	Aug 14 BMO	Avg Volume	31.60K	Price	2.33
SMA20	-36.17%	SMA50	-46.10%	SMA200	-59.43%	Trades		Volume	82,749	Change	-1.69%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-21	Upgrade	Maxim Group	Hold → Buy	$12
Nov-17-20	Downgrade	Maxim Group	Buy → Hold
Dec-19-16	Reiterated	Maxim Group	Buy	$5 → $6
Dec-22-15	Reiterated	Maxim Group	Buy	$14 → $5

Sep-24-24 06:00AM	BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting (PR Newswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) -5.67%
Aug-14-24 07:05AM	BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-24 06:00AM	BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update (PR Newswire)
Jul-24-24 08:30AM	BCLI Update - Progress Supports Our 10x Plus Value Range Potential (PR Newswire) +6.10%
06:00AM	Loading…
Jul-01-24 06:00AM	BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program (PR Newswire) +5.47%
Jun-27-24 09:15AM	BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering (PR Newswire) -7.87%
Jun-26-24 08:00AM	BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn Clinical Trial (PR Newswire)
Jun-20-24 06:00AM	BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer (PR Newswire)
Jun-14-24 12:01PM	BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn Clinical Effectiveness Expectation (PR Newswire) +6.09%
May-20-24 06:00AM	BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn (PR Newswire) +9.02%
May-14-24 10:53PM	BCLI Stock Earnings: Brainstorm Cell Reported Results for Q1 2024 (InvestorPlace) -8.74%
04:30PM	BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-01-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +15.10%
Apr-16-24 06:30PM	BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn (PR Newswire)
06:00AM	Loading…
Apr-11-24 06:00AM	BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule (PR Newswire)
Apr-10-24 06:00AM	BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's Phase 3 Clinical Trial in ALS (PR Newswire)
Apr-09-24 06:00AM	BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS (PR Newswire) -20.21%
Apr-08-24 06:00AM	BrainStorm Cell Therapeutics to Provide Update on NurOwn Program (PR Newswire) +12.14%
Apr-01-24 08:05AM	BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +31.03%
Feb-27-24 06:30AM	BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference (PR Newswire)
Feb-23-24 06:00AM	BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS (PR Newswire) +5.60%
Feb-13-24 06:30AM	BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum (PR Newswire) -5.63%
Dec-27-23 09:30AM	BRAINSTORM SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options (GlobeNewswire) +24.35%
Dec-26-23 07:30AM	BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments (PR Newswire) +16.40%
Dec-20-23 09:00AM	BrainStorm Issues 2023 Letter to Shareholders (PR Newswire)
Dec-07-23 08:40AM	BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn in ALS (PR Newswire) -25.33%
Nov-20-23 08:10AM	BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn in ALS (PR Newswire)
Nov-17-23 07:00AM	BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia (PR Newswire)
Nov-15-23 01:53PM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript (Insider Monkey)
03:29AM	Loading…
03:29AM	Q3 2023 Brainstorm Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:05AM	BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-08-23 08:00AM	BRAINSTORM SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options (PR Newswire)
Nov-07-23 06:00AM	BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire) +10.82%
Oct-24-23 07:00AM	BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS (PR Newswire) -8.28%
Oct-23-23 10:05AM	BCLI: Meeting with FDA to Discuss Development Plan for NurOwn® (Zacks) -5.67%
Oct-18-23 08:01AM	BrainStorm, after setbacks, withdraws approval application for ALS drug (BioPharma Dive)
06:00AM	BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS (PR Newswire)
Oct-02-23 07:00AM	BCLI: Advisory Panel Votes Against Recommending Approval of NurOwn® (Zacks)
Sep-27-23 10:48PM	BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS (PR Newswire)
06:15PM	FDA advisers vote against experimental ALS treatment pushed by patients (Associated Press Finance)
07:00AM	BrainStorm Cell Therapeutics Stock Trading Halted Today (PR Newswire)
Sep-26-23 12:17PM	BCLI: Public Support for NurOwn® from Prominent ALS Specialists (Zacks) -8.35%
Sep-25-23 08:13AM	FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy (Reuters) -47.57%
Aug-18-23 08:34AM	BCLI: Preparing for AdCom on September 27, 2023 (Zacks)
Aug-15-23 03:11AM	Q2 2023 Brainstorm Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.59%
Aug-14-23 07:05AM	BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-23 04:05PM	BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
Jul-17-23 09:15AM	Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering (PR Newswire) -5.58%
Jul-12-23 07:00AM	BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer (PR Newswire)
Jul-07-23 07:00AM	BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration (PR Newswire)
Jun-20-23 09:06AM	BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair (PR Newswire) -14.12%
Jun-16-23 07:00AM	BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual Conference (PR Newswire)
Jun-06-23 06:00AM	BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023 (PR Newswire)
May-23-23 11:35AM	BCLI: Awaiting Adcom Date for NurOwn® (Zacks Small Cap Research)
May-19-23 07:30AM	BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit (PR Newswire)
May-18-23 08:55AM	While institutions own 23% of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), retail investors are its largest shareholders with 59% ownership (Simply Wall St.)
May-17-23 02:41PM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 07:05AM	BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-09-23 06:00AM	BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
Apr-24-23 07:00AM	BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer (PR Newswire)
Apr-07-23 07:30AM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Apr-05-23 07:46PM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.62%
Apr-04-23 09:12AM	BCLI: Preparing for Adcom for NurOwn® (Zacks Small Cap Research) -10.70%
Mar-30-23 07:05AM	BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-27-23 09:15AM	BCLI: FDA Grants Adcom for NurOwn® (Zacks Small Cap Research)
06:00AM	BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS (PR Newswire)
Mar-21-23 08:18AM	BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update (PR Newswire)
Jan-10-23 07:00AM	BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study (PR Newswire)
Jan-05-23 07:30AM	BrainStorm Cell Therapeutics to Present at Biotech Showcase 2023 (PR Newswire) -5.52%
Jan-04-23 07:30AM	BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer (PR Newswire)
Dec-27-22 06:00AM	BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn® (PR Newswire) -12.35%
Dec-12-22 07:00AM	BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration (PR Newswire) +35.77%
Nov-17-22 06:56AM	The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen (Zacks) -8.33%
06:15AM	BCLI: Receives a Refusal to File Letter from the FDA for NurOwn® BLA (Zacks Small Cap Research)
Nov-16-22 11:28AM	Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More (Zacks)
Nov-14-22 07:05AM	BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update (PR Newswire) +7.89%
Nov-10-22 11:01AM	FDA Refuses To Accept BrainStorm Cell's Lead Candidate For Amyotrophic Lateral Sclerosis (Benzinga) -42.21%
08:30AM	BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS (PR Newswire)
Nov-07-22 04:10PM	BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update (PR Newswire)
06:00AM	BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting (PR Newswire)
Oct-20-22 06:00AM	BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress (PR Newswire) -8.09%
Oct-07-22 12:00PM	BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium (PR Newswire) -8.52%
Oct-04-22 06:00AM	BCLI: Relvyrio Approval Shows FDA Flexibility for ALS Treatments (Zacks Small Cap Research)
Sep-15-22 06:00AM	BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis Journal (PR Newswire)
Aug-30-22 08:20AM	We Think Brainstorm Cell Therapeutics (NASDAQ:BCLI) Needs To Drive Business Growth Carefully (Simply Wall St.)
Aug-17-22 10:16AM	BCLI: Filing a BLA for NurOwn® for the Treatment of ALS (Zacks Small Cap Research) +11.92%
Aug-15-22 07:05AM	BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update (PR Newswire)
Aug-01-22 06:00AM	BrainStorm to Announce Second Quarter Results and Provide a Corporate Update (PR Newswire) +6.25%
May-31-22 06:00AM	BrainStorm Announces Presentations at June 2022 Scientific Conferences (PR Newswire)
May-24-22 07:10AM	BCLI: Anticipating News on How NurOwn® Will be Advanced Forward (Zacks Small Cap Research)
May-16-22 08:00AM	Edited Transcript of BCLI.OQ earnings conference call or presentation 16-May-22 12:00pm GMT (Thomson Reuters StreetEvents)
07:05AM	BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update (PR Newswire)
May-12-22 08:02AM	BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal (PR Newswire)
May-04-22 06:00AM	BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting (PR Newswire)
May-03-22 06:00AM	BrainStorm Announces Upcoming Scientific Conference Presentations (PR Newswire)
May-02-22 06:00AM	BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update (PR Newswire)
Apr-04-22 06:20AM	BCLI: Awaiting Clarity on Regulatory Environment Before Deciding on Next Steps for NurOwn® (Zacks Small Cap Research)
Mar-28-22 09:00AM	Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT (PR Newswire)
07:05AM	BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update (PR Newswire)

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lebovits Chaim	President & CEO	Oct 01 '24	Buy	3.43	1,836	6,292	80,960	Oct 02 08:00 AM
Lebovits Chaim	President & CEO	Sep 30 '24	Buy	0.23	22,000	5,016	1,186,865	Oct 02 08:00 AM
Dagher Ibrahim B.	Chief Medical Officer	Jul 19 '24	Sale	0.35	63,000	22,069	0	Jul 24 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCLI

Brainstorm Cell Therapeutics, Inc.

Upgrade your FINVIZ experience